Pharmacokinetic Profiling of Norucholic Acid in Patients with Primary Sclerosing Cholangitis: A Clinical Study

The primary objective of this study is to characterize the **pharmacokinetic** profile of norucholic acid (NCA) in patients diagnosed with **Primary Sclerosing Cholangitis (PSC)**. Understanding the pharmacokinetics of NCA is clinically relevant as it may provide insights into the drug's absorption, distribution, metabolism, and excretion in this specific patient population, potentially informing dosing strategies and therapeutic efficacy. No secondary objectives are provided for this study.

The clinical trial involves a total of **10 participants** diagnosed with **Primary Sclerosing Cholangitis (PSC)**. The study population includes both male and female subjects, with an age range that spans from **18 to 64 years**. Participants were selected to include a vulnerable population, although specific criteria for vulnerability are not detailed. The trial does not specify any particular lifestyle considerations such as diet or physical activity. The selection process for the trial population is not elaborated upon, and no principal inclusion or exclusion criteria are provided. The general health status of the participants is not described beyond their diagnosis with PSC.

The clinical trial is designed to evaluate the **pharmacokinetic** profile of norucholic acid in patients diagnosed with **Primary Sclerosing Cholangitis (PSC)**. This study is structured as a Phase 3 trial, which is a critical stage in the clinical research process, focusing on the efficacy and safety of the investigational product. The trial employs a randomized, double-blind, controlled design to ensure the reliability and validity of the results. The estimated duration of the trial extends from July 20, 2023, to December 31, 2024, providing a comprehensive timeline for data collection and analysis.

Participants will undergo a series of study visits, beginning with an inclusion visit, also known as the screening visit, where eligibility criteria are assessed. This initial visit is crucial for determining participant suitability based on predefined inclusion and exclusion criteria. Following successful screening, participants will be randomized into treatment groups. Throughout the trial, follow-up visits will be scheduled at regular intervals to monitor the participants' health status, adherence to the study protocol, and any adverse events. These visits are essential for collecting ongoing data and ensuring participant safety. The trial will conclude with an end-of-study visit, where final assessments are conducted, and participants are debriefed on the study outcomes.

The expected length of participant involvement in the trial is approximately 18 months, contingent upon the individual's adherence to the study protocol and absence of any adverse events that may necessitate early termination. Conditions that could lead to early withdrawal from the study include significant protocol deviations, adverse reactions to the investigational product, or voluntary withdrawal by the participant. The trial's design and procedures are meticulously crafted to uphold the highest standards of scientific rigor and ethical responsibility, ensuring the integrity of the data collected and the safety of all participants involved.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it has an **orphan drug** designation. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In addition to the experimental medication, the trial may include the use of **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatments. However, the data does not provide explicit details about these treatments. Information regarding the administration, dosing schedules, and participant compliance monitoring for both experimental and non-experimental treatments is not available in the provided data.

The clinical trial is designed to assess efficacy within a Phase 3 framework. The trial is scheduled to commence recruitment on July 20, 2023, with an estimated completion date of December 31, 2024. Efficacy will be evaluated using specific parameters or endpoints, although these are not detailed in the provided data. The trial will follow a structured methodology for measuring, collecting, and analyzing these efficacy parameters, adhering to the rigorous standards typical of Phase 3 trials. The assessment will likely involve validated scales, laboratory tests, or patient-reported outcomes, measured at predetermined timepoints throughout the trial duration. The trial's design ensures that efficacy assessments are conducted systematically to provide reliable and scientifically valid results.